James Wang
Co-founder and CTO / COO @ Lioness
Berkeley, United States
James Wang is a co-founder of Lioness, currently serving as CTO and COO. His specialities management, software development, and statistical analysis and learning (AI/machine learning). Previously, he spearheaded the launch announcement and branding for Google X's Makani project pilot in Hawaii, led a team of analysts at BridgewaterAssociates, and co-founded and managed a consulting group specializing in microfinance in the developing world.James holds an MBA from UC Berkeley where he was a Jack Larson Fellow in Entrepreneurship, a BA with Honors from Dartmouth, and is an MS Computer Science candidate at Georgia Tech. He also holds a Data Science Specialization from the John Hopkins Bloomberg School of Public Health and completed the course track for a PhD Designated Emphasis in Computational Sciences and Engineering at Berkeley.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries James Wang invests in
Stages James Wang invests in
Countries James Wang invests in
Investment Focus
Industry
- Health Care 3 (100%)
- Software 2 (67%)
- Biotechnology 2 (67%)
- Medical Device 2 (67%)
- Medical 1 (33%)
Country
- Canada 1 (33%)
- Argentina 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
OncoPrecision
|
We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity and Resistance Test, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access toPrecision Oncology and improve cancer patients' lives. | $3.3M / Seed / Aug 01, 2022 | |
Oncoustics AI
|
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers. | $5M / Seed / Jul 21, 2022 | |
C. Light Technologies
|
C. Light is a neurotech company utilizing advanced machine learning and the most accurate commercially-available eye tracker (by 150X) to assess neurological health, starting with multiple sclerosis. it is a developer of a retinal eye-tracking platform used to improve the monitoring of neurodegenerative diseases. | $4.1M / Seed / Feb 02, 2021 |
Co-Investors
Band of Angels
1 deal together
Berkeley SkyDeck Fund
1 deal together
Fraser Kearney Capital Corp.
1 deal together
Fundacion para el Progreso de la Medicina
1 deal together
GRID EXPONENTIAL
1 deal together
About Lioness
Lioness is a team of designers and engineers building a vibrator that helps you understand, discover, and take control of your own body, paired with an app that allows you to easily visualize what your body is telling you and ask questions to a supportive community. Using advanced biometric sensing and statistical methods, we help you characterizeyour sexuality—how fast you get aroused, how long it generally takes to orgasm, and when sex would feel best—both individually and within the diverse sexual spectrum of the aggregate female population.Finally, as a company with strong female technology, design, and executive leadership, their product is women-centric at its core, from their choices to use the same materials as those used in medical devices to tailoring their device's ergonomics to how women actually hold vibrators. Changing the conversation around female sexuality is hard, but their team is determined to take on the challenge.
Lioness Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anna Lee
Co-Founder and Lead Engineer
|
|||
|
Betsy Rohney
Community Manager
|
|||
|
James Wang
Co-founder and CTO / COO
|
|||
Leo Chen
Hardware Lead
|
|||
Liz Klinger
Co-founder & CEO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does James Wang invest in?
James Wang invests primarily in Health Care, Software and Biotechnology startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did James Wang last invest?
The most recent investment recorded for James Wang closed in Aug 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
